sacubitril has been researched along with Atrial-Remodeling* in 1 studies
1 other study(ies) available for sacubitril and Atrial-Remodeling
| Article | Year |
|---|---|
Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Sacubitril/valsartan (Sac/Val, LCZ696), the world's first angiotensin receptor-neprilysin inhibitor (ARNi), has been widely used in the treatment of heart failure. However, the use of Sac/Val in the treatment of atrial fibrillation (AF), especially AF with hypertension, has been less reported. We investigated the effect of Sac/Val on atrial remodeling and hypertension-related AF.. The AF induction rate and electrophysiological characteristics of spontaneously hypertensive rats (SHRs) treated with Sac/Val or Val were detected by rapid atrial pacing and electrical mapping/optical mapping. The whole-cell patch-clamp and Western blot were used to observe electrical/structural remodeling of atrial myocytes/tissue of rats and atrium-derived HL-1 cells cultured under 40 mmHg in vitro.. Sac/Val can improve atrial structural and electrical remodeling induced by hypertension and reduce the AF susceptibility by inhibiting RAS and NEP. The above effects of Sac/Val were superior to Val alone. Topics: Aminobutyrates; Angiotensins; Animals; Antihypertensive Agents; Atrial Fibrillation; Atrial Remodeling; Biphenyl Compounds; Drug Combinations; Hypertension; Neprilysin; Rats; Rats, Inbred SHR; Tetrazoles; Valsartan | 2023 |